An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects

To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.

Inclusion Criteria:

• Healthy male subjects aged 30 to 65 years of age.
• Male subjects and their partners must agree to use an adequate method of contraception
• Historically able to produce a minimum of 1 bowel movement every day on most days

Exclusion Criteria:

• Female subjects
• Use of any medication or supplement within 5 days prior to Dosing
• Radiation exposure exceeding 5 millisieverts (mSv) in the last 12 months or 10 mSv in the last 5 years
• Current smokers or the use of cigarettes within 90 days prior to Screening
• History or renal disease or abnormal kidney function
• History of hepatic disease
• Acute diarrhea or constipation within 7 days of dosing
• Positive urine glucose at Screening